Chapter 2. Psychotropic Medications

  1. Dr Neil Harris BSc (Hons), RNM, RGN, PSI Diploma, PhD, Consultant Nurse Lecturer4,
  2. Dr John Baker MPhil, MSc, BNurs (Hons), RMN, CPN, PhD, postgraduate Lecturer4 and
  3. Professor Richard Gray PhD, MSc, BSc (Hons), RN, Dip HE, DLSHTM, FEANS Professor5
  1. Howard Chadwick Senior Lecturer Trainer1,2 and
  2. Dan Bressington Senior Lecturer3

Published Online: 27 OCT 2009

DOI: 10.1002/9781444316155.ch2

Medicines Management in Mental Health Care

Medicines Management in Mental Health Care

How to Cite

Chadwick, H. and Bressington, D. (2009) Psychotropic Medications, in Medicines Management in Mental Health Care (eds N. Harris, J. Baker and R. Gray), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444316155.ch2

Editor Information

  1. 4

    University of Manchester, UK

  2. 5

    University of East Anglia, Norwich, UK

Author Information

  1. 1

    Kingston University, UK

  2. 2

    St George's London University, UK

  3. 3

    Department of Social Work, Community and Mental Health, Canterbury Christ Church University, UK

Publication History

  1. Published Online: 27 OCT 2009
  2. Published Print: 15 MAY 2009

ISBN Information

Print ISBN: 9781405132893

Online ISBN: 9781444316155



  • psychotropic medications;
  • mental health nurses and role in psychiatric medication management;
  • key medication management issues relating to drug class;
  • antipsychotic medication for treating psychosis symptoms;
  • dopaminergic side effects;
  • tardive dyskinesia (TD);
  • neuroleptic malignant syndrome (NMS);
  • atypical antipsychotics - low propensity inducing EPSEs;
  • third-generation antipsychotics;
  • pharmacological treatment options for bipolar disorder - lithium salts, anti-convulsants and antipsychotics


This chapter contains sections titled:

  • Introduction

  • Antipsychotics

  • Typical antipsychotics

  • Atypical antipsychotics

  • Third-generation antipsychotics

  • Mood stabilisers

  • Lithium

  • Anti-convulsants

  • Antipsychotics

  • Antidepressants

  • Anti-anxiety medicines

  • Benzodiazepines

  • Medicines for dementia

  • Danger zones – areas of risk with psychotropics

  • Conclusion

  • References